0.9050 0.00 (0.52%)
Pre-Market: 6:04AM EDT
|Bid||0.9050 x 4000|
|Ask||0.0000 x 1200|
|Day's Range||0.8675 - 0.9090|
|52 Week Range||0.4050 - 3.5400|
|Beta (5Y Monthly)||2.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 12, 2020 - Aug 17, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.33|
Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that the company has begun enrolling cluster headache patients in the ATAC clinical trial. This Phase 2/3 study will evaluate the efficacy of C213 for the acute treatment of cluster headache. C213 is the company’s investigational proprietary formulation of zolmitriptan delivered utilizing its proprietary ADAM patch technology, which consists of titanium micro-projections coated with drug and is the same formulation as QtryptaTM, for the acute treatment of migraine.
FREMONT, Calif., Sept. 26, 2019 -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief.
Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced an oral presentation and two poster presentations of positive data from a one-year long-term safety study of Qtrypta™ for the acute treatment of migraine were presented at the 19th Congress of the International Headache Society (IHC) in Dublin, Ireland. The Qtrypta long-term safety study was an open-label trial evaluating the safety of a 3.8 mg dose of intracutaneous zolmitriptan in adults with migraine who had historically experienced at least 2 migraine attacks per month.
Oral presentation of the safety and efficacy of QtryptaTM in a long-term safety study for the acute treatment of migraine.Poster on the results of patients’ freedom from pain.
Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that Hayley Lewis, senior vice president of operations at Zosano Pharma, will be presenting a keynote speech entitled, “A Novel Intracutaneous Microneedle Delivery System for the Acute Treatment of Migraine” at the Pharmaceutics & Advanced Drug Delivery Systems Conference in Paris on July 5, 2019 at 09:15 am CET. Ms. Lewis’ presentation will review Zosano’s novel and proprietary technology platform, the chemistry, manufacturing, and controls of the company’s lead asset, Qtrypta.